Array
(
[id] => 2154
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2154.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:42
[updatetime] => 2024-12-19 09:42:42
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => When specific reversal agents are unavailable,PCC or activated PCC should be considered for reversing NOAC effects.(Evidence: Level C，Recommendation: Class IIa)
[laiyuan] => 当没有特定的逆转剂时，应考虑使用凝血酶原复合物浓缩物或活化凝血酶原复合物浓缩物来逆转非维生素K口服抗凝剂效应。（证据级别：C；推荐强度：IIa）
[znzldj] => A
[_inputtime] => 1734572562
[_updatetime] => 1734572562
[_nrjc] =>
[_nrsh] =>
)
推荐意见
当没有特定的逆转剂时，应考虑使用凝血酶原复合物浓缩物或活化凝血酶原复合物浓缩物来逆转非维生素K口服抗凝剂效应。（证据级别：C；推荐强度：IIa）
When specific reversal agents are unavailable,PCC or activated PCC should be considered for reversing NOAC effects.(Evidence: Level C，Recommendation: Class IIa)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2155
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2155.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:42
[updatetime] => 2024-12-19 09:42:42
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => If an urgent surgical intervention is required,specific coagulation tests and assessment of NOAC plasma levels should be considered to interpret routine coagulation tests and waning of anticoagulant effect.(Evidence: Level C，Recommendation: Class IIa)
[laiyuan] => 紧急手术时应考虑用特殊的凝血试验和NOAC血浆水平测定解释常规凝血检验和抗凝作用的消退。（证据级别：C；推荐强度：IIa）
[znzldj] => A
[_inputtime] => 1734572562
[_updatetime] => 1734572562
[_nrjc] =>
[_nrsh] =>
)
推荐意见
紧急手术时应考虑用特殊的凝血试验和NOAC血浆水平测定解释常规凝血检验和抗凝作用的消退。（证据级别：C；推荐强度：IIa）
If an urgent surgical intervention is required,specific coagulation tests and assessment of NOAC plasma levels should be considered to interpret routine coagulation tests and waning of anticoagulant effect.(Evidence: Level C，Recommendation: Class IIa)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2156
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2156.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:42
[updatetime] => 2024-12-19 09:42:42
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => In minor bleeding risk surgery and other procedures where bleeding can be easily controlled, it is recommended to perform surgery without interruption of OAC therapy.(Evidence: Level B，Recommendation: Class I)
[laiyuan] => 对于出血风险小的手术和其他操作，因出血容易控制，术前可以不停口服抗凝剂。（证据级别：B；推荐强度：I）
[znzldj] => A
[_inputtime] => 1734572562
[_updatetime] => 1734572562
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于出血风险小的手术和其他操作，因出血容易控制，术前可以不停口服抗凝剂。（证据级别：B；推荐强度：I）
In minor bleeding risk surgery and other procedures where bleeding can be easily controlled, it is recommended to perform surgery without interruption of OAC therapy.(Evidence: Level B，Recommendation: Class I)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2157
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2157.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:42
[updatetime] => 2024-12-19 09:42:42
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => LMWH is recommended, as an alternative to UFH, for bridging in patients with MHVs and high surgical risk.(Evidence: Level B，Recommendation: Class I)
[laiyuan] => 行高风险手术的心脏机械瓣患者应使用低分子肝素替代普通肝素进行桥接。（证据级别：B；推荐强度：I）
[znzldj] => A
[_inputtime] => 1734572562
[_updatetime] => 1734572562
[_nrjc] =>
[_nrsh] =>
)
推荐意见
行高风险手术的心脏机械瓣患者应使用低分子肝素替代普通肝素进行桥接。（证据级别：B；推荐强度：I）
LMWH is recommended, as an alternative to UFH, for bridging in patients with MHVs and high surgical risk.(Evidence: Level B，Recommendation: Class I)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2158
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2158.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:42
[updatetime] => 2024-12-19 09:42:42
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => In patients using NOACs, it is recommended that minor bleeding risk procedures are performed at trough levels (typically 12–24 h after last intake).(Evidence: Level C，Recommendation: Class Ⅰ)
[laiyuan] => 使用NOAC抗凝的患者，应在药物达低谷水平（最后一次用药后12～24 h）时进行出血风险小的手术。（证据级别：C；推荐强度：I）
[znzldj] => A
[_inputtime] => 1734572562
[_updatetime] => 1734572562
[_nrjc] =>
[_nrsh] =>
)
推荐意见
使用NOAC抗凝的患者，应在药物达低谷水平（最后一次用药后12～24 h）时进行出血风险小的手术。（证据级别：C；推荐强度：I）
In patients using NOACs, it is recommended that minor bleeding risk procedures are performed at trough levels (typically 12–24 h after last intake).(Evidence: Level C，Recommendation: Class Ⅰ)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2159
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2159.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:42
[updatetime] => 2024-12-19 09:42:42
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => For patients with mechanical prosthetic heart valves undergoing NCS, bridging with UFH or LMWH should be considered if OAC interruption is needed and patients have: (i) mechanical AVR
and any thromboembolic risk factor; (ii)old-generation mechanical AVR; or (iii)mechanical mitral or tricuspid valve replacement.(Evidence: Level C，Recommendation: Class IIa)
[laiyuan] => 心脏机械瓣患者行NCS手术时，如果是：（i）主动脉瓣机械置换和有任何血栓栓塞危险因素，（ii）老一代主动脉机械瓣置换，（iii）二尖瓣或三尖瓣机械瓣置换，需要暂停口服抗凝剂时，应使用低分子肝素或肝素进行桥接。（证据级别：C；推荐强度：IIa）
[znzldj] => A
[_inputtime] => 1734572562
[_updatetime] => 1734572562
[_nrjc] =>
[_nrsh] =>
)
推荐意见
心脏机械瓣患者行NCS手术时，如果是：（i）主动脉瓣机械置换和有任何血栓栓塞危险因素，（ii）老一代主动脉机械瓣置换，（iii）二尖瓣或三尖瓣机械瓣置换，需要暂停口服抗凝剂时，应使用低分子肝素或肝素进行桥接。（证据级别：C；推荐强度：IIa）
For patients with mechanical prosthetic heart valves undergoing NCS, bridging with UFH or LMWH should be considered if OAC interruption is needed and patients have: (i) mechanical AVR
and any thromboembolic risk factor; (ii)old-generation mechanical AVR; or (iii)mechanical mitral or tricuspid valve replacement.(Evidence: Level C，Recommendation: Class IIa)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2160
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2160.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:42
[updatetime] => 2024-12-19 09:42:42
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => Bridging of OAC therapy is not recommended inpatients with low/moderate thrombotic riskundergoing NCS.(Evidence: Level B，Recommendation: Class III)
[laiyuan] => 对于接受非心脏手术治疗的低/中度血栓风险患者，不建议使用口服抗凝剂桥接疗法。（证据级别：B；推荐强度：Ⅲ）
[znzldj] => A
[_inputtime] => 1734572562
[_updatetime] => 1734572562
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于接受非心脏手术治疗的低/中度血栓风险患者，不建议使用口服抗凝剂桥接疗法。（证据级别：B；推荐强度：Ⅲ）
Bridging of OAC therapy is not recommended inpatients with low/moderate thrombotic riskundergoing NCS.(Evidence: Level B，Recommendation: Class III)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2161
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2161.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:42
[updatetime] => 2024-12-19 09:42:42
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => If bleeding risk with resumption of full-dose anticoagulation outweighs the risk of thromboembolic events, postponing therapeutic anticoagulation 48–72 h after the procedure may be considered, using post-operative thromboprophylaxis until resumption of full OAC
dose is deemed safe.(Evidence: Level C ，Recommendation: Class IIb)
[laiyuan] => 如果恢复全量抗凝剂的出血风险超过血栓栓塞事件风险，应延迟治疗剂量的抗凝剂至术后48～72 h，并使用术后血栓预防直到恢复全量口服抗凝剂被认为是安全的。（证据级别：C；推荐强度：IIb）
[znzldj] => A
[_inputtime] => 1734572562
[_updatetime] => 1734572562
[_nrjc] =>
[_nrsh] =>
)
推荐意见
如果恢复全量抗凝剂的出血风险超过血栓栓塞事件风险，应延迟治疗剂量的抗凝剂至术后48～72 h，并使用术后血栓预防直到恢复全量口服抗凝剂被认为是安全的。（证据级别：C；推荐强度：IIb）
If bleeding risk with resumption of full-dose anticoagulation outweighs the risk of thromboembolic events, postponing therapeutic anticoagulation 48–72 h after the procedure may be considered, using post-operative thromboprophylaxis until resumption of full OAC
dose is deemed safe.(Evidence: Level C ，Recommendation: Class IIb)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2162
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2162.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:42
[updatetime] => 2024-12-19 09:42:42
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => Use of reduced-dose NOAC to attenuate the risk of post-operative bleeding is not recommended.(Evidence: Level C，Recommendation: Class III)
[laiyuan] => 不推荐 NOAC 减量使用以减轻术后出血风险。（证据级别：C；推荐强度：Ⅲ）
[znzldj] => A
[_inputtime] => 1734572562
[_updatetime] => 1734572562
[_nrjc] =>
[_nrsh] =>
)
推荐意见
不推荐 NOAC 减量使用以减轻术后出血风险。（证据级别：C；推荐强度：Ⅲ）
Use of reduced-dose NOAC to attenuate the risk of post-operative bleeding is not recommended.(Evidence: Level C，Recommendation: Class III)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 2163
[catid] => 311
[title] => 2022 ESC Guidelines on cardiovascular
assessment and management of patients
undergoing non-cardiac surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 3
[author] => 甘肃中医院
[status] => 9
[url] => https://www.anes-guide.com/show/2163.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.116
[inputtime] => 2024-12-19 09:42:42
[updatetime] => 2024-12-19 09:42:42
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36017553/
[demo_url] =>
[zjpjff] => LOE
[zjfj] =>
[tjqd] =>
[nianfen] => 2022
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => It is recommended that decisions about peri-operative thromboprophylaxis in NCS are based on individual and procedure-specific risk factors.(Evidence: Level A ，Recommendation: Class I)
[laiyuan] => 非心脏手术的围术期血栓预防应基于患者个体和手术特定的危险因素进行。（证据级别：A；推荐强度：I）
[znzldj] => A
[_inputtime] => 1734572562
[_updatetime] => 1734572562
[_nrjc] =>
[_nrsh] =>
)
推荐意见
非心脏手术的围术期血栓预防应基于患者个体和手术特定的危险因素进行。（证据级别：A；推荐强度：I）
It is recommended that decisions about peri-operative thromboprophylaxis in NCS are based on individual and procedure-specific risk factors.(Evidence: Level A ，Recommendation: Class I)
证据评价方法：LOE
指南质量等级：A
年份：2022
国家：the European Society of Anaesthesiology and Intens
